Atara Biotherapeutics Inc (ATRA) Share Price

$30++++ fda decision on the 15th

$30++++ fda decision on the 15th

...

ATRA under $13

ATRA under $10

ATRA under $10

Taking another ride here.

Broke $1M traded again.....finally.

ATRA: THANKS to BOTH of you Fellows for the EARLY heads-up!!!

7.77m VOL NICE, I LIKE TPET FOR A 4AM GAPPER


T31M OS TRADED 2X ALREADY

FLOAT ROTATION 3X


LOOKING FOR .40-50

ATRA looks good

Having a good day despite the offering currently up 20%

https://ih.advfn.com/stock-market/NASDAQ/atara-biotherapeutics-ATRA/stock-news/92982254/atara-biotherapeutics-announces-15-million-regist

Although I'm gonna say no. However, in this cockeyed market, we don't know. We are dealing with a different universe brother. Very strange

hmmmmm .70 wonder if this will continue tomorrow


os and float same 95M

https://finviz.com/quote.ashx?t=ATRA&ty=c&ta=1&p=d

NEWS
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). Building on the earlier partnership announced in October 2021 to commercialize tab-cel in Europe, this transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets.

“We are pleased to announce the closing of the transaction with Pierre Fabre Laboratories who are committed to expanding the reach of tab-cel to patients in the U.S. and across the globe,” said Pascal Touchon, President and Chief Executive Officer of Atara. “Atara’s priority is to now submit the tab-cel BLA filing package, while initiating our first clinical study with ATA3219, a potential best-in-class allogeneic off-the-shelf CD19 CAR T with unique features.”

With the closing of the transaction, Atara will receive approximately USD 27 million in cash upfront and initial inventory purchase. Under the agreement, Atara has the potential to receive up to a total of USD 640 million and significant double-digit tiered royalties on net sales, including up to USD 100 million in potential regulatory milestones through BLA approval. In addition, Pierre Fabre Laboratories will reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer, and purchase future tab-cel inventory through the manufacturing transfer date.

Substantially all tab-cel manufacturing, clinical, and regulatory activities are planned to transition from Atara to Pierre Fabre Laboratories at the time of BLA transfer.

Atara plans to submit the BLA to the U.S. Food and Drug Administration (FDA) for tab-cel for the treatment of post-transplant lymphoproliferative disease (PTLD) in the second quarter of 2024.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X (formerly known as Twitter) and LinkedIn.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel®, including a potential BLA, the potential characteristics and benefits of tab-cel®, and the progress and results of, prospects for, and closing of the expanded global partnership with Pierre Fabre Laboratories involving tab-cel®, and the potential financial benefits to Atara as a result of the expanded global partnership with Pierre Fabre Laboratories; (2) the development, t

ATRA under $2

Can be squeezing too hard with a 17% drop in price. ??????

E. F. Hutton analyst maintains a BUY with a $25 target!!!! Why did ATRA do so badly today with a 17% decline??? Any thoughts. I am holding but...........

Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by JPMorgan Chase & Co. to Overweight

Posted by ABMN Staff on May 19th, 2021

Atara Biotherapeutics logoAtara Biotherapeutics (NASDAQ:ATRA) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a $29.00 price objective on the biotechnology company’s stock, up from their prior price objective of $23.00. JPMorgan Chase & Co.‘s target price points to a potential upside of 99.59% from the company’s previous close.

Several other research firms have also issued reports on ATRA. HC Wainwright reduced their price target on shares of Atara Biotherapeutics from $32.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, May 11th. Citigroup raised Atara Biotherapeutics from a “neutral” rating to a “buy” rating and set a $27.00 target price on the stock in a report on Tuesday, March 2nd. Finally, William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a report on Tuesday, March 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $34.33.

Shares of NASDAQ ATRA opened at $14.53 on Wednesday. The business has a fifty day moving average price of $14.06 and a two-hundred day moving average price of $17.83. The stock has a market capitalization of $1.22 billion, a PE ratio of -3.15 and a beta of 2.65. Atara Biotherapeutics has a fifty-two week low of $8.90 and a fifty-two week high of $28.20.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, May 3rd. The biotechnology company reported ($0.86) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.06. As a group, equities research analysts expect that Atara Biotherapeutics will post -3.89 earnings per share for the current fiscal year.
In other Atara Biotherapeutics news, CFO Utpal Koppikar sold 1,761 shares of the business’s stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $14.58, for a total transaction of $25,675.38. Following the sale, the chief financial officer now directly owns 172,582 shares of the company’s stock, valued at approximately $2,516,245.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joe Newell sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 15th. The shares were sold at an average price of $17.41, for a total transaction of $121,870.00. Following the completion of the transaction, the chief operating officer now owns 145,219 shares of the company’s stock, valued at $2,528,262.79. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,901 shares of company stock worth $238,537. 4.30% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the stock. Signaturefd LLC raised its position in Atara Biotherapeutics by 6,757.1% during the 1st quarter. Signaturefd LLC now owns 2,400 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,365 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Atara Biotherapeutics by 181.5% during the fourth quarter. Penserra Capital Management LLC now owns 1,785 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,151 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Atara Biotherapeutics by 50.9% in the first quarter. Pacer Advisors Inc. now owns 4,608 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 1,554 shares during the period. Nisa Investment Advisors LLC increased its position in Atara Biotherapeutics by 589.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,620 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 3,950 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in Atara Biotherapeutics in the first quarter valued at $118,000.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Breaking News: $ATRA Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara’s allogeneic CAR T therapy leverages the combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies built on the Company’s novel EBV T-cell platform Preclinical findings demonstrate potent antitumor activity, persistence a...

In case you are interested ATRA - Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

$ATRA bears are running Atara Biotherapeutics Inc Nasdaq Atra Short Squeeze

News: $ATRA Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference call and webcast today at 3:30 p.m. CEST / 9:30 a.m. EDT ...

In case you are interested ATRA - Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

News: $ATRA Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was well-tolerated and showed encouraging anti-tumor activity in combination with pembrolizumab, a PD-1 checkpoint inhibitor  Best overall r...

Read the whole news https://marketwirenews.com/news-releases/atara-biotherapeutics-announces-collaborator-presentation-of-positive-phase-1-clinical-results-for-a-mesothelin-targeted-car-t-immunotherapy-in-patients-with-advanced-mesothelioma-7919490.html

Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclero DJNF
Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to proceed with patient enrollment at U.S. sites for its ongoing global Phase 1 clinical study to evaluate ATA188 in patients with progressive or relapsing-remitting multiple sclerosis (MS). ATA188, the Company's off-the-shelf T-cell immunotherapy using a complementary targeted antigen recognition technology licensed from QIMR Berghofer Medical Research Institute, selectively targets specific Epstein-Barr virus (EBV) antigens believed to play an important role in the pathogenesis of MS. Atara initiated the open-label, single arm Phase 1 study in MS patients in the fourth quarter of 2017 in Australia.

"We are pleased with FDA's decision to allow off-the-shelf ATA188 to proceed into clinical development in patients with MS in the U.S.," said Chris Haqq M.D., Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Atara Biotherapeutics. "We believe that an off-the-shelf T-cell immunotherapy such as ATA188 may allow for a more consistent reactivity against target EBV antigens, which may be correlated with clinical improvements based on data from a previous autologous ATA190 Phase 1 study in patients with progressive MS. We look forward to the first results from the ATA188 Phase 1 study in patients with progressive MS in the first half of

BRIDGER MANAGEMENT, LLC has filed a new 13G, reporting 5.2% ownership in $ATRA - https://fintel.io/so/us/atra

ATRA bullish 21.12

Need this to drop 10%

All sellers no buyers... Down she goes

I've been shorting this the past few days, easy money

Atara’s Discontinuation Paints it as a Potential Short

http://marketexclusive.com/ataras-discontinuation-paints-it-as-a-potential-short/1173/

Keep on falling

Down she goes......

I see the uptrend. Stock is breaking the resistance line and the downward trendline!

could double from here

$ATRA recent news/filings

bullish
symmetrical triangle breakout soon

## source: finance.yahoo.com

Fri, 10 Jul 2015 05:11:00 GMT ~ 1:11 am Atara Biotherapeutics prices offering of 3,461,538 shares of its common stock at $52.00 per share


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#atra
*********************************************************

Fri, 10 Jul 2015 00:31:02 GMT ~ Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock

[at noodls] - SOUTH SAN FRANCISCO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating ...

read full: http://www.noodls.com/view/C39E7CB948A50C763B65D33B826D5A82DC6BDA32
*********************************************************

Fri, 10 Jul 2015 00:08:28 GMT ~ Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Atara Biotherapeutics, Inc. , a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the pricing ...

read full: http://finance.yahoo.com/news/atara-bio-announces-pricing-180-000828259.html
*********************************************************

Tue, 07 Jul 2015 20:47:09 GMT ~ Atara Bio Announces Proposed Offering of Common Stock

[at noodls] - SOUTH SAN FRANCISCO, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating ...

read full: http://www.noodls.com/view/D36C89829CB05A1A21C48C50D9F60376308A5299
*********************************************************

Tue, 07 Jul 2015 20:05:00 GMT ~ Atara Bio Announces Proposed Offering of Common Stock

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Atara Biotherapeutics, Inc. , a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it ...

read full: http://finance.yahoo.com/news/atara-bio-announces-proposed-offering-200500993.html
*********************************************************

$ATRA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ATRA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ATRA/company-info
Ticker: $ATRA
OTC Market Place: Not Available
CIK code: not found
Company name: Atara Biotherapeutics, Inc.
Incorporated In:

$ATRA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ATRA extra dd links

Company name: Atara Biotherapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ATRA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ATRA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ATRA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/news - http://finance.yahoo.com/q/h?s=ATRA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ATRA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ATRA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ATRA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Atara+Biotherapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Atara+Biotherapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Atara+Biotherapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ATRA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ATRA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ATRA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ATRA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ATRA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ATRA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ATRA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ATRA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ATRA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ATRA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ATRA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ATRA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ATRA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ATRA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ATRA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ATRA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ATRA



$ATRA DD Notes ~ http://www.ddnotesmaker.com/ATRA

On watch......

$ATRA recent news/filings

bullish
bullish engulfing

## source: finance.yahoo.com

Wed, 29 Apr 2015 22:15:16 GMT ~ Nasdaq stocks posting largest percentage decreases

[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220242625--finance.html
*********************************************************

Tue, 28 Apr 2015 12:38:12 GMT ~ Atara Biotherapeutics (ATRA) Falls: Stock Goes Down 19.4% - Tale of the Tape


read full: http://finance.yahoo.com/news/atara-biotherapeutics-atra-falls-stock-123812970.html
*********************************************************

Mon, 20 Apr 2015 10:46:49 GMT ~ EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

[at noodls] - SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center ...

read full: http://www.noodls.com/view/F5E86C4ED97E6021996505EB6A500C5F8341F79F
*********************************************************

Mon, 20 Apr 2015 10:30:00 GMT ~ EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Atara Biotherapeutics, Inc. today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic ...

read full: http://finance.yahoo.com/news/ebv-ctl-clinical-trial-data-103000068.html
*********************************************************

Sun, 19 Apr 2015 12:55:12 GMT ~ Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available

[at noodls] - SOUTH SAN FRANCISCO, Calif., April 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus ...

read full: http://www.noodls.com/view/CFC4866E6F03B003009024E6E4A9953CC6962A7A
*********************************************************

$ATRA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ATRA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ATRA/company-info
Ticker: $ATRA
OTC Market Place: Not Available
CIK code: not found
Company name: Atara Biotherapeutics, Inc.
Incorporated In:

$ATRA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ATRA extra dd links

Company name: Atara Biotherapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ATRA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ATRA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ATRA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/news - http://finance.yahoo.com/q/h?s=ATRA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ATRA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ATRA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ATRA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Atara+Biotherapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Atara+Biotherapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Atara+Biotherapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ATRA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ATRA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ATRA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ATRA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ATRA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ATRA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ATRA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ATRA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ATRA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ATRA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ATRA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ATRA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ATRA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ATRA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ATRA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ATRA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ATRA



$ATRA DD Notes ~ http://www.ddnotesmaker.com/ATRA